Today's trial-design narrative review becomes the quarter's methodological flashpoint, generating multiple editorials on blinding and monitor standardization.

A recently published review paper — one that lays out problems with how psychedelic drug trials are designed and overseen — is on track to become a major talking point in the scientific community. Expect multiple published responses and opinion pieces arguing about whether these trials can be trusted. This is the scientific version of a food fight, and it matters because the outcome shapes what future studies have to look like.

Consensus of 3 agents: fda_reviewer, neuroscientist, maps_researcher. 0 dissenting.